2024-10-07 - Analysis Report
## AMGN (Amgen Inc.) Stock Analysis Report

**Company Overview:** Amgen Inc. is a global biotechnology company that develops, manufactures, and markets pharmaceuticals used in the treatment of serious illnesses.

**1. Performance Analysis:**

* **Cumulative Return:** 78.76%
* **S&P 500 (VOO) Cumulative Return:** 133.14%
* **Return Difference:** -54.38%
* **Relative Divergence:** 31.65% (meaning AMGN's performance is currently 31.65% below the S&P 500's historical range)

**2. Recent Price Movement:**

* **Closing Price:** 319.66
* **5-Day Moving Average:** 319.88
* **20-Day Moving Average:** 327.44
* **60-Day Moving Average:** 328.38

**3. Technical Indicators:**

* **RSI:** 37.08 (indicating a potentially oversold condition)
* **PPO:** -0.43 (suggesting a bearish sentiment)
* **Delta_Previous_Relative_Divergence:** -13.26 (short-term downtrend)
* **Expected Return:** 0.0% (over the next 5 years, compared to S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

The latest earnings report (2024-08-07) showed an EPS of 1.39, exceeding analysts' expectations. Revenue also came in slightly above forecasts. This suggests that the company continues to perform well despite the challenging market conditions.

**5. News and Recent Issues:**

Recent market outlook for AMGN is mixed. Some analysts see potential for growth in its key product lines, particularly in the emerging markets. However, others are concerned about the company's dependence on a few blockbuster drugs and the increasing competition in the biopharmaceutical industry. 

According to FINBOLD, AMGN has been downgraded by several analysts recently, citing concerns over its potential for further growth. 

**6. Overall Analysis:**

AMGN currently trades below the S&P 500's performance. Despite recent positive earnings results, technical indicators suggest a bearish sentiment and potential for further downside. Analysts' opinions are mixed, with some seeing growth opportunities and others expressing concern about the competitive landscape. 

**7. Recommendations:**

While AMGN has a strong history of innovation and a large portfolio of medications, its current performance is below the market average. Given the mixed outlook and recent analyst downgrades, investors should exercise caution and consider a wait-and-see approach. 

**Disclaimer:** This analysis is based on publicly available information and should not be considered financial advice. 
